Chapter 301 (1/2)
”Pa pa pa pa...”
”Pa pa pa pa pa...”
The scholars on the spot gave Zhou Wen the warmest applause, which was quite different from the sparse applause at the beginning.
Zhou Wen expressed his thanks several times and nodded to the audience, all of which received warm applause again.
Three times later, the applause finally faded away.
Zhou Wen said slowly: ”as we all know, unlike healthy cells, cancer cells are constantly dividing and need to synthesize new DNA and RNA to support the production of new cells.
However, through our unremitting research, we found that early lung cancer has unexpected weaknesses, especially relying on pyrimidine biosynthesis pathway, and a lanthanum methylase, which we call methyllanthanum enzyme, can effectively resist it in cell lines and mouse models... ”
With Zhou Wen's complaint, thousands of lung cancer experts and scholars under the stage gradually showed a color of surprise.
”With more in-depth research, we have made a breakthrough in the treatment of early lung cancer!”
After a pause, as the experts held their breath and concentrated, Zhou Wen said: ”we have successfully resisted the invasion of early lung cancer by taking advantage of this weakness, and further effectively killed it.”
With Zhou Wen's speech, the big screen behind him lights up, and the experimental data map appears on it.
Zhou bowed his head and slid the iPad on the podium, while the data graph on the big screen moved left and right.
”Code dst-104, this is the first simulation experiment three months ago, mainly aimed at EGFR, ALK, CMET, ros1, HER2, KRAS and so on This is the second animal experiment two months ago... ”
With Zhou Wen's explanation, the scene was silent at first, but it gradually became boiling.
Numerous experts and scholars began to discuss it aloud.
”Dr. Aung Naing didn't say that the effect of anti-PD-1 monoclonal antibody treatment was not good. Why did he have the opposite reaction?”
”Well, you see, the sequence of the dihydrolactate dehydrogenase gene has changed.”
”Why is the reaction mode of this methyllanthanum enzyme so strange...”
Zhou Wen's experimental data, like throwing a huge stone under the calm lake, instantly set off a huge wave.
There are more and more comments from lung cancer experts.
However, those medical professionals, representatives of pharmaceutical companies, as well as those listening to lung cancer patients who do not have a thorough understanding of lung cancer can not understand the complicated theoretical knowledge and target map, but they understand Zhou Wen's words that early lung cancer can be completely cured.
”What he said is true. Can early lung cancer be completely cured?”
”No way. There was no news before.”
”This guy is a galdena prize winner, so he shouldn't talk nonsense...”
Wu Yilong, sitting in the middle, was also very surprised at this time.
He had been speculating before that, how could Zhou Wen, a researcher of biological viruses, appear at the lung cancer conference, but he did not expect that he had made a breakthrough in the field of lung cancer research.
”Teacher, how true is this data?” Asked the assistant sitting next to Wu Yilong.
Wu Yilong looked at the experimental data on the big screen for a moment and said solemnly: ”it's not sure yet. We need to do the experiment to know.”
After a pause of half a second, Wu Yilong said, ”but this man is a medical genius. He has made brilliant achievements in oncology. It is very likely that he is true.”
The assistant looked at the data on the big screen with a look of shock on his face.
His teacher has been studying lung cancer for 20 years. Although he has made remarkable achievements, most of them are based on foreign research results.
As Zhou Wen directly attacks early lung cancer, especially small cell lung cancer, which accounts for 15% of the total number of lung cancer, due to the high degree of malignancy and limited treatment measures, so far, there are no approved targeted drugs in the world.
Zhou Wen even declared that it could be cured. It was really frightening.
And since it has a curative effect on early lung cancer, it shows that it is also quite effective for middle and advanced lung cancer.
Why isn't that shocking?
The buzz is getting louder and louder.
In particular, those tumor and lung cancer experts are full of question marks, but Zhou Wen has already stepped down from the stage.
After chatting with the people around him, Ronald, the host, opened his mouth and said, ”cough First of all, I would like to thank Professor Zhou Wen for his wonderful speech. Just now Dr. Taylor and Prof. Nicholas have said that they will give you 10 minutes to ask questions, Professor Zhou... ”
Zhou Wen, who had just arrived at his seat, said with a smile: ”good...”
……
The news that early lung cancer has been conquered has no accident and quickly reached the mainstream media of Singapore, China, France, Italy, Germany, Russia and other major countries in the world.Soon, the United States, the United Kingdom, South Korea, Australia, New Zealand and other countries also reported.
In private, numerous Lung Cancer Institutes and pharmaceutical companies in western countries were surprised and stunned when they heard the news.
Every year, they make tens of millions of dollars from the western countries in the field of cancer research, and they are in the forefront of the world in terms of research and treatment.
But I didn't expect that this time, Chinese pharmaceutical enterprises took the lead in the research.
And those pharmaceutical giants in Europe and the United States, at the beginning, were a little stunned, but when they saw Zhou Wen's name, the color of amazement on their faces quickly returned to normal.
These pharmaceutical giants have a better understanding of Zhou Wen.
In addition to speeding up the development of new drugs, they also launched a more in-depth commercial investigation on Zhou Wen and Huanyu biopharmaceuticals.
On October 13, universal biology held its first press conference in Jiangzhou Taihu International Conference Center.
Mainly on HIV specific drugs, anti sensitivity new drugs, lung cancer new drugs and other questions.
More than 1600 journalists from more than 70 countries attended the press conference.
For the first time, Cosmos came to the front desk from behind the scenes.
The press conference was broadcast live.
Luo Zongwei, vice president and director of marketing and operation Department, answered more than 60 questions raised by reporters.
For the first time, many people have learned about the scientific research strength of the whole world.
For example, there are more than 400 researchers with doctor's degree in its laboratories, and more than 1500 master's and undergraduate graduate students graduated from key universities.
”Our investment in scientific research is also very huge. In the first half of 2020, the salary expenditure of personnel alone will reach 750 million, and the experimental fund will exceed 2 billion.”
”In such a cost-effective investment, the output is naturally very gratifying.”
”For example, the biological ointment just launched has a very good effect on various skin diseases. For example, ichthyosis, folliculitis, scleroderma, psoriasis and so on, these have been verified
”There are also...”
Taking the opportunity of the press conference, Luo Zongwei also missed the opportunity to promote the company's products
The magnesium light flickered on the scene of the press conference, and the major pharmaceutical companies at home and abroad basically paid attention to this conference.
Foreign Pfizer, Novartis, Roche, mocuo, Sanofi, gunfire, Gilead science, GlaxoSmithKline, Aberdeen, Amgen, AstraZeneca, elgene, etc.
Domestic companies such as Hengrui, Mairui, Yaoming Kant, alli health, Yunnan medicine, Hengda health, sinopharma holdings, Zhifei biology, Yaoming biology, Shiyao group, etc.
The research results in front of them make the executives and shareholders of these companies envious and jealous.
However, their talent pool also makes many domestic companies feel inferior to them,
of course, they know that doctors are good, and students graduated from key universities are smart, and the key is that they can't afford it.
A Ph.D. student should get at least two or three hundred thousand a year, right?
How many are ten?
How many are a hundred?
In addition, how much salary should be paid to the master's and undergraduate students in key universities every year?
These are all money!
There are also experimental supplies and so on.
Such a huge investment in scientific research is comparable to those of the large pharmaceutical enterprises in China.
However, when Luo Zongwei talks about scientific research output, many people are dismissive and disdainful.